NASDAQ:PMD Psychemedics (PMD) Stock Price, News & Analysis → If you own NVIDIA, read this now (From Porter & Company) (Ad) Free PMD Stock Alerts $2.57 -0.12 (-4.46%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$2.55▼$2.5750-Day Range$2.53▼$3.0552-Week Range$2.06▼$5.15Volume1,983 shsAverage Volume5,251 shsMarket Capitalization$14.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Psychemedics alerts: Email Address Ad Porter & CompanyIf you own NVIDIA, read this now Forget investing in Nvidia or Microsoft. Because there is only ONE AI company that matters. It’s a U.S-based firm you’ve never heard of before – one that isn’t even involved in the artificial intelligence conversation. But here’s what nobody else has spotted: without this company’s new technology, the entire AI market could collapse. I call it “The AI Keystone.” About Psychemedics Stock (NASDAQ:PMD)Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.Read More PMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMD Stock News HeadlinesMay 17, 2024 | money.usnews.comPsychemedics Corp.May 16, 2024 | investing.comPsychemedics (PMD) Earnings Dates & ReportsMay 14, 2024 | msn.comPMD Stock Earnings: Psychemedics Reported Results for Q1 2024May 14, 2024 | sfgate.comPsychemedics: Q1 Earnings SnapshotMay 14, 2024 | globenewswire.comPsychemedics Corporation Reports First Quarter 2024 Financial ResultsApril 25, 2024 | finance.yahoo.comPsychemedics Corporation (PMD) Stock Price, News, Quote & History - Yahoo FinanceMarch 28, 2024 | investorplace.comPMD Stock Earnings: Psychemedics Reported Results for Q4 2023March 28, 2024 | globenewswire.comPsychemedics Corporation Reports 2023 Financial ResultsMarch 21, 2024 | globenewswire.comPsychemedics Recognized as a Top 10 Employee Health Testing Services ProviderJanuary 3, 2024 | bizjournals.comSmall cap drug testing company relocates HQ to DFW from MassachusettsJanuary 2, 2024 | msn.comMassachusetts drug testing firm targeting fentanyl relocates corporate HQ to DallasJanuary 2, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Relocation of Headquarters to Dallas, TexasNovember 10, 2023 | msn.comPsychemedics reports Q3 resultsNovember 9, 2023 | finance.yahoo.comPsychemedics Corporation Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | morningstar.comPsychemedics Corp PMDOctober 27, 2023 | finance.yahoo.comUnveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug ScreenSeptember 26, 2023 | benzinga.comPsychemedics Chief Revenue Officer Awarded $448K Worth of Stock OptionsSeptember 22, 2023 | benzinga.comPsychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue OfficerSeptember 21, 2023 | msn.comDo You Get PMS? You Could Be Headed for Early Menopause, Study ShowsAugust 22, 2023 | benzinga.comPresident & CEO at Psychemedics Acquires Company Stock Options Worth 300,000 SharesAugust 18, 2023 | finance.yahoo.comPsychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2023 | marketwatch.comPsychemedics 2Q Loss Widens Amid Labor Shortage, SettlementAugust 11, 2023 | marketwatch.comPsychemedics Eliminates DividendAugust 11, 2023 | finance.yahoo.comPsychemedics Corporation Reports Second Quarter 2023 Financial ResultsJuly 12, 2023 | marketwatch.comPsychemedics Taps Brian Hullinger as Successor of Long-Time CEO Ray KubackiSee More Headlines Receive PMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/25/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:PMD CUSIPN/A CIK806517 Webwww.psychemedics.com Phone(978) 206-8220Fax978-264-9236Employees116Year Founded1985Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,150,000.00 Net Margins-20.23% Pretax Margin-16.10% Return on Equity-59.21% Return on Assets-32.38% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.48 Sales & Book Value Annual Sales$22.10 million Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book2.38Miscellaneous Outstanding Shares5,810,000Free Float4,413,000Market Cap$14.93 million OptionableNot Optionable Beta0.69 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Brian Hullinger (Age 56)President, CEO & Director Comp: $361.37kMs. Daniella Mehalik (Age 34)Vice President of Finance Comp: $126.41kMs. Shannon ShoemakerChief Revenue OfficerDr. Werner A. Baumgartner Ph.D.FounderMs. Annette BaumgartnerFounderMr. Michael Weisenhoff (Age 34)Principal Financial & Accounting Manager Mr. Patrick J. Kinney Jr.SecretaryMore ExecutivesKey CompetitorsEnzo BiochemNYSE:ENZRenalytixNASDAQ:RNLXExagenNASDAQ:XGNDermTechNASDAQ:DMTKBioNexus Gene LabNASDAQ:BGLCView All CompetitorsInsidersCharles M DoucotSold 12,700 sharesTotal: $59,182.00 ($4.66/share)View All Insider Transactions PMD Stock Analysis - Frequently Asked Questions How have PMD shares performed in 2024? Psychemedics' stock was trading at $2.96 on January 1st, 2024. Since then, PMD stock has decreased by 13.2% and is now trading at $2.57. View the best growth stocks for 2024 here. When is Psychemedics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our PMD earnings forecast. How were Psychemedics' earnings last quarter? Psychemedics Co. (NASDAQ:PMD) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.12) earnings per share for the quarter. The company earned $5.36 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 59.21% and a negative net margin of 20.23%. What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO? 6 employees have rated Psychemedics Chief Executive Officer Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among the company's employees. What other stocks do shareholders of Psychemedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG). How do I buy shares of Psychemedics? Shares of PMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PMD) was last updated on 5/25/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersUrgent Nvidia WarningAltimetryBiden FINISHED On June 13th?Paradigm PressThis could mean the end of the U.S dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psychemedics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.